stoxline Quote Chart Rank Option Currency Glossary
Galera Therapeutics, Inc. (GRTX)
0.09  -0.004 (-4.26%)    06-17 15:57
Open: 0.0921
High: 0.0967
Volume: 463,820
Pre. Close: 0.094
Low: 0.082
Market Cap: 5(M)
Technical analysis
2024-06-17 5:23:50 PM
Short term     
Mid term     
Targets 6-month :  0.2 1-year :  0.27
Resists First :  0.17 Second :  0.23
Pivot price 0.13
Supports First :  0.08 Second :  0.06
MAs MA(5) :  0.09 MA(20) :  0.14
MA(100) :  0.18 MA(250) :  0.52
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  3 D(3) :  2.3
RSI RSI(14): 30
52-week High :  3.19 Low :  0.08
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GRTX ] has closed above bottom band by 26.9%. Bollinger Bands are 151% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.1 - 0.1 0.1 - 0.1
Low: 0.08 - 0.08 0.08 - 0.08
Close: 0.09 - 0.09 0.09 - 0.09
Company Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Headline News

Fri, 14 Jun 2024
Why Galera Therapeutics (GRTX) Stock Is Nosediving - MSN

Mon, 03 Jun 2024
Galera Therapeutics Receives Written Notice From Nasdaq Indicating That Nasdaq Hearings Panel Determined To ... - XM

Mon, 03 Jun 2024
Why Galera Therapeutics (GRTX) Stock Is Nosediving - Galera Therapeutics (OTC:GRTX) - Benzinga

Tue, 14 May 2024
Galera Therapeutics Explores Strategic Options Amid Financial Results Announcement - MyChesCo

Mon, 13 May 2024
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates - Yahoo Finance

Fri, 03 May 2024
Galera Therapeutics Enacts Plan to Deter Hostile Takeovers - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 54 (M)
Shares Float 36 (M)
Held by Insiders 36.1 (%)
Held by Institutions 18.9 (%)
Shares Short 2,120 (K)
Shares Short P.Month 2,660 (K)
Stock Financials
EPS -0.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.49
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -59.3 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.69
Qtrly Earnings Growth 0 %
Operating Cash Flow -38 (M)
Levered Free Cash Flow -29 (M)
Stock Valuations
PE Ratio -0.1
PEG Ratio 0
Price to Book value -0.04
Price to Sales 0
Price to Cash Flow -0.13
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android